Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 31Lymphoma 19Neoplasms, Plasma Cell 16Myelodysplastic Syndromes 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 13Leukemia, Myeloid, Acute 13Leukemia 13Hodgkin Disease 12Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 7Retinoblastoma 6Lymphoma, Mantle-Cell 6Burkitt Lymphoma 6Myeloproliferative Disorders 5Immunoglobulin Light-chain Amyloidosis 5Recurrence 4Primary Myelofibrosis 4Ovarian Neoplasms 4Neuroblastoma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Juvenile 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hematologic Neoplasms 4Congenital Abnormalities 4Sezary Syndrome 3Myelodysplastic-Myeloproliferative Diseases 3

Interventions

Rituximab 4Cyclophosphamide 4Etoposide 3Dexamethasone 3ponatinib 2pomalidomide 2fludarabine 2Whole-Body Irradiation 2Vincristine 2Sirolimus 2Prednisone 2Platelet Transfusion 2Mycophenolic Acid 2Lenalidomide 2Ifosfamide 2Doxorubicin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2Alemtuzumab 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2ricolinostat 1pembrolizumab 1nilotinib 1ibrutinib 1fludarabine phosphate 1epratuzumab 1daratumumab 1dacetuzumab 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hematologic Diseases × Melphalan × Clear all
NCT01359254 2015-04-30

Cord Blood Transplantation for Patients With Cancer

University of Chicago

Phase 2 Terminated
1 enrolled 4 charts

Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡